Platelet-Regulated Immune Responses in Neonates Following Transfusion
新生儿输血后血小板调节的免疫反应
基本信息
- 批准号:10039184
- 负责人:
- 金额:$ 23.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-15 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdultAdverse effectsAffectBiological Response ModifiersBiologyBirth WeightBlood PlateletsClinical ResearchComparative StudyDataDevelopmentDevelopmental BiologyFutureGoalsHematopoiesisHematopoieticHemorrhageHumanImmuneImmune responseImmune systemIn VitroInfantInflammatoryInflammatory ResponseKnowledgeLeadMediatingModelingMusNecrotizing EnterocolitisNeonatalNewborn InfantPhenotypePlatelet TransfusionPremature InfantProteinsProteomeRetinal DiseasesRiskRoleSafetySepsisSignal TransductionTestingThrombocytopeniaTransforming Growth Factor alphaTransfusionadverse outcomedifferential expressionimmune functionimprovedin vivoin vivo Modelin vivo evaluationinduced pluripotent stem cellinsightmonocyteneonatenovelpreventprogramsprophylacticresponsetraffickingtranscriptome
项目摘要
Project Summary
This proposal brings together the expertise of the Palis and Morrell labs in developmental
hematopoiesis and platelet biology, respectively, in order to gain a mechanistic understanding of the
complications associated with platelet transfusions into neonates. Thrombocytopenia is common in
newborns, particularly in premature infants. Platelet transfusions are prophylactically used to prevent
bleeding, but recent clinical studies have shown that the transfusion of platelets to neonates, while perhaps
reducing bleeding risk, can increase serious and sometimes long-term complications including
retinopathies, necrotizing enterocolitis and sepsis. We therefore seek to better understand the mechanisms
that contribute to these platelet-mediated adverse outcomes. Our long-term aim is to mitigate their adverse
effects of platelet transfusions and ultimately develop ex vivo modified platelets, including platelets derived
from induced pluripotent stem (iPS) cells, to increase the safety of transfusion therapy for neonates.
We have discovered that, compared to adult platelets, neonatal platelets differentially express several
immune-related molecules. These data lead to our overall hypothesis that the transfusion of adult platelets
into neonates drives an inflammatory phenotype in monocyte leading to adverse complications. This
hypothesis is further supported by our preliminary data utilizing a novel murine neonatal transfusion model,
where monocyte inflammatory responses were enhanced by adult, but not neonatal, platelet transfusions.
We will utilize this in vivo model to define platelet-driven immune responses, focusing on the causative role
of platelet-derived immune mediators in the activation of monocytes both in vitro and in vivo. Finally, to
obtain a deeper understanding of the developmental program of adult versus neonatal platelets, we will
initiate comparative studies of murine and human platelet transcriptomes and proteomes, focusing on the
differential expression of immune-related molecules.
Completion of this project will establish fundamental insights regarding the developmental biology of
platelets and their ability to interact with the immune system of neonates. This knowledge will lay the
groundwork for future studies in re-programming platelet immune functions to improve safety and efficacy of
platelet transfusions both for neonates and adults.
项目摘要
该提案汇集了Palis和Morrell实验室在发展方面的专业知识,
造血和血小板生物学,分别,以获得一个机制的理解,
新生儿血小板输注相关并发症。血小板减少症常见于
新生儿,特别是早产儿。血小板输注可用于预防
出血,但最近的临床研究表明,血小板输注给新生儿,而也许
减少出血风险,可能会增加严重的,有时是长期的并发症,包括
视网膜病变、坏死性小肠结肠炎和败血症。因此,我们寻求更好地了解这些机制,
导致这些血小板介导的不良后果。我们的长期目标是减轻他们的不利影响,
血小板输注的影响,并最终开发出体外修饰的血小板,包括血小板衍生的
从诱导多能干细胞(iPS),以提高新生儿输血治疗的安全性。
我们已经发现,与成人血小板相比,新生儿血小板差异表达几种
免疫相关分子。这些数据导致我们的总体假设,即输注成人血小板
进入新生儿驱动单核细胞中的炎性表型,导致不良并发症。这
我们利用新的鼠新生儿输血模型的初步数据进一步支持了这一假设,
其中单核细胞炎性反应被成人血小板输注增强,但未被新生儿血小板输注增强。
我们将利用这种体内模型来定义血小板驱动的免疫反应,重点是致病作用,
血小板衍生的免疫介质在单核细胞的激活在体外和体内。最后为
为了更深入地了解成人与新生儿血小板的发育程序,我们将
启动小鼠和人类血小板转录组和蛋白质组的比较研究,重点是
免疫相关分子的差异表达。
该项目的完成将建立关于发育生物学的基本见解,
血小板及其与新生儿免疫系统相互作用的能力。这一知识将奠定
为未来研究重新编程血小板免疫功能以提高安全性和有效性奠定基础
新生儿和成人的血小板输注。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CRAIG N MORRELL其他文献
CRAIG N MORRELL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CRAIG N MORRELL', 18)}}的其他基金
Platelet-Regulated Immune Responses in Neonates Following Transfusion
新生儿输血后血小板调节的免疫反应
- 批准号:
10217253 - 财政年份:2020
- 资助金额:
$ 23.1万 - 项目类别:
ERK5 and CD36 link oxidative stress to platelet dysfunction and ischemic injury
ERK5 和 CD36 将氧化应激与血小板功能障碍和缺血性损伤联系起来
- 批准号:
10323025 - 财政年份:2019
- 资助金额:
$ 23.1万 - 项目类别:
Novel mechanisms of platelet modified monocyte phenotype
血小板修饰单核细胞表型的新机制
- 批准号:
10166903 - 财政年份:2018
- 资助金额:
$ 23.1万 - 项目类别:
Novel mechanisms of platelet modified monocyte phenotype
血小板修饰单核细胞表型的新机制
- 批准号:
10377113 - 财政年份:2018
- 资助金额:
$ 23.1万 - 项目类别:
Novel platelet functions for in T-cell helper cell responses
T 细胞辅助细胞反应中的血小板新功能
- 批准号:
9385749 - 财政年份:2014
- 资助金额:
$ 23.1万 - 项目类别:
Novel platelet functions for in T-cell helper cell responses
T 细胞辅助细胞反应中的血小板新功能
- 批准号:
8967578 - 财政年份:2014
- 资助金额:
$ 23.1万 - 项目类别:
Novel platelet functions for in T-cell helper cell responses
T 细胞辅助细胞反应中的血小板新功能
- 批准号:
8814885 - 财政年份:2014
- 资助金额:
$ 23.1万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 23.1万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 23.1万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 23.1万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 23.1万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 23.1万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 23.1万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 23.1万 - 项目类别:
Discovery Grants Program - Individual